Hepatocellular Carcinoma (HCC)Phase 1/2SPKTAHCNCT07636785
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
A Phase 1/2 study testing VMD-102 in people with Hepatocellular Carcinoma (HCC) and Metastatic Uveal Melanoma, run by VM Discovery, Inc. at 1 site in United States.
Trial summary
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC)
- What is being tested?
- VMD-102
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 111 participants
- Where
- 1 siteUnited States
- Study dates
- 16 Jul 2026to Dec 2031
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histological or cytological or radiological diagnosis of advanced (unresectable and/or metastatic) HCC, MUM, RCC, NSCLC and CRC that is not responsive to standard of care (SOC), had progressed following SOC, is intolerant to SOC, or for whom the SOC is not considered appropriate by the investigator.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0, or 1.
- Has at least one measurable target lesion according to RECIST v1.1 [Response Evaluation Criteria In Solid Tumors], or mRECIST [modified RECIST] for unresectable HCC participants, and either (a). has not been previously treated with local therapy (e.g., radiation therapy, hepatic arterial embolization, radiofrequency ablation, and percutaneous interventional therapy), or (b). if the target lesion was within the field of local therapy, the lesion has shown an increase in size of 25% or greater following local therapy.
- Adequate organ function evidenced by:
- Hematology
- Hemoglobin ≥ 9 g/dL (SI Units: 90 g/L) (post-transfusion if transfusion-dependent)
Show all 26Show fewer
- Platelet count ≥ 60000/mm3 (60 x109/L) without support(transfusion) within 7 days of testing
- Absolute neutrophil count (ANC) ≥ 1500/mm3 (1.5x109/L) Chemistry
- Total bilirubin (TBIL) ≤ 2.0 x upper limit of normal (ULN). (For participants with Gilbert's syndrome, TBIL ≤3.0 x ULN provided that direct bilirubin DBIL) is <30% of the TBIL)
- Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) 1 ≤ 5 x U LN (participants with advanced HCC or liver metastases)
- AST and/or ALT 1 ≤ 3 x ULN (participants without known liver disease or liver metastases)
- Calculated creatinine clearance or 24h urine creatinine clearance ≥50 mL/min using Cockroft-Gault formula.
- Serum creatinine ≤ 1.5x ULN
- Coagulation (unless taking an anti-coagulant):
- Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (except for participants receiving therapeutic anticoagulants)
- International normalized ratio (INR) ≤ 1.5 unless the participant is receiving anticoagulant therapy as long as the participant is within therapeutic range of intended use of anticoagulants
- Albumin ≥2.8g/d/L.
- For HCC participants: the diagnosis must be made based on American Association for the Study of Liver Diseases (AASLD) Guidelines with confirmed advanced (unresectable) HCC staged by Barcelona Clinic Liver cancer criteria (BCLC). Cirrhosis will be staged by Child-Pugh score, and such a score ≤ 6 will be eligible for Phase 1 and ≤7 for Phase 2.
- Participants must either have available archival tumor tissue samples, or consent to fresh tumor tissue sampling prior to the first dose unless the biopsy is not safe or not feasible per investigator assessment and with medical monitor approval.
- Women of childbearing potential (WOCBP) must have a negative pregnancy test prior to enrolment and agree to use a highly effective and acceptable method of contraception from the time of informed consent (or screening) until 6 months after the last dose of investigational agent.
- Male participants who are sexually active with a female partner of childbearing potential must agree to use a condom with spermicide from first dose of investigational agent until 6 months after the last dose, and refrain from sperm donation during that period. Abstinence from heterosexual intercourse is an acceptable method only if the participant's usual lifestyle already includes abstinence.
- Participant has a life expectancy of ≥3 months.
- No history of liver transplantation.
- Ability to swallow and absorb an orally self-administered medication in tablet form.
- Have completed any prior chemotherapy, monoclonal antibody or immunotherapy (e.g., tumor vaccine, cytokine, or growth factor given to control the cancer) at least 4 weeks or 5 half-lives (whichever is shorter) before study drug administration. Exceptions to these prior therapy timeframes are possible, on a case by case basis, following discussion and mutual agreement between Investigator and Sponsor.
- Adverse effects related to prior anticancer therapies must have either returned to baseline or resolved to Grade 0 or 1. Some toxicities with higher grades such as alopecia, immunotherapy-induced hypothyroidism or adrenal insufficiency or panhypopituitarism requiring stable doses of hormone replacement therapy or rash from prior therapy may be permitted with medical monitor approval.
Who cannot join
- Received anticancer therapy with radiation, immunotherapy, a biologic, surgery and/or tumor embolization within the past 2 weeks or 5 half-lives (whichever is longer).
- Currently pregnant, nursing, or planning to become pregnant during the course of study.
- The Fridericia Corrected QT (QTcF) interval ≥ 480 msec.
- Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system (Section 14.8); or presence of clinically significant and uncontrolled cardiac disease, as assessed by the investigator. Such as but not limited to: symptomatic congestive heart failure, unstable angina, cardiac arrhythmia.
- Unstable or uncompensated respiratory, hepatic, renal, or cardiac disease that would compromise the participant's safety or interfere with assessment of the drug.
- Psychological, familial, sociological, geographical or other concurrent conditions that would interfere with safety evaluation, limit the participant's ability to follow the procedures in the protocol or otherwise jeopardize compliance with the protocol. Participants with uncontrolled major depression, bipolar disorder, or severe anxiety disorder are excluded.
Show all 31Show fewer
- Participants have multiple factors that affect their oral medication (such as inability to swallow and intestinal obstruction or resection).
- Participants have long-term unhealed wounds or fractures.
- Participants have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage.
- Any current medical conditions, including impairment of GI function or GI disease, which would alter the absorption, distribution, metabolism or excretion of VMD-102 including but not limited to:
- Severe uncontrolled nausea or vomiting.
- Severe uncontrolled diarrhea or ongoing active diarrhea requires medications (e.g. bile acid sequestrant, loperamide).
- A history of short bowel syndrome; irritable bowel syndrome with diarrheal signs/symptoms or require medications.
- Clinically diagnosed malabsorption secondary to bowel resection.
- Active Ulcerative colitis or Crohn's disease requiring medication for control.
- Surgical procedures of the GI tract impacting the drug absorption such as but not limited to small bowel resection and gastric bypass.
- Unstable central nervous system (CNS) metastases. Participants with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least one cycle prior to the first dose and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are on stable doses of steroids for at least one cycle prior to the first dose.
- Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC or HCC due to cirrhosis caused from autoimmune-associated hepatitis.
- Hepatitis B surface antigen (HBsAg) positive with detectable the hepatitis B virus load (HBV DNA) >100 IU/mL. Participants on active HBV therapy with viral loads <100 IU/mL should stay on the same therapy throughout study intervention and at least 12 weeks after the study is over. Participants cannot be actively co-infected with hepatitis C virus (HCV; HCV RNA detectable) or hepatitis delta virus (HDV; HDV RNA detectable).
- Positive HBsAg, with or without detectable HBV DNA, if there is evidence in the medical history of an advanced stage of cirrhosis ( Child-Pugh B) or history of decompensated chronic liver disease
- HCV antibody (HCVAb) positive and HCV viral load (HCV RNA) detectable. Previous HCVAb positive with HCV RNA undetectable due to treatment (DAAs or interferon) is allowed but the treated participants must have completed their treatment at least 12 weeks prior to starting study intervention and HCV RNA must be documented at below the limit of quantification.
- History of allogeneic tissue/organ transplantation (including bone marrow, stem cell, liver, or kidney transplants), except those that do not require immunosuppressive therapy (e.g., corneal or hair transplants).
- Coronavirus disease 2019 (COVID-19) or any live attenuated vaccine within 4 weeks of study entry.
- Participants with active alcohol and/or substances abuse, Phosphatidylethanol (Peth) must be <50 ng/mL).
- Concurrent secondary malignancy other than that being treated in this study. Exceptions to this exclusion include malignancies treated curatively and have not recurred within 2 years prior to study entry or tumors treated with curative intent that have expected cure rates of >90% such as but not limited to: basal cell and squamous skin cancer and completely resected carcinoma in situs.
- Participants have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage. Exception may be possible, on a case by case basis, e.g. if no more than one paracentesis in a month and a drain is pre-placed for the participant to drain, following discussion and mutual agreement between Investigator and Sponsor
- Participants have long-term unhealed wounds or fractures.
- Participants receiving known potent P-glycoprotein (P-gp) efflux transporter inhibitors that cannot be discontinued 3 days prior to the start of study treatment and during the course of the Phase 1 study.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drug, or excipients.
- Known history of uncontrolled human immunodeficiency virus (HIV) infection.
- Any other condition that, in the opinion of the Investigator or the medical monitor, could increase the risk to the participant, interfere with study participation, or affect the proper interpretation of study results and objectives. Such conditions may include but are not limited to, active infections, uncontrolled diabetes, psychiatric illness, social situations, and concomitant therapies.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
HonorHealth Research Institute
Scottsdale, Arizona, 85258
Study Coordinator, 480-323-1350, clinicaltrials@honorhealth.com
Justin C Moser, MD
About this study
Official title: A Phase 1 and 2 First-in-human, Open-label, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of VMD-102 in Participants With Hepatocellular Carcinoma and Other Advanced Solid Tumors
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The pharmacokinetics (PK), preliminary anti-tumor activity, and potential biomarkers of VMD-102 will also be assessed.
VMD-102 will be the first selective PKC epsilon (PKCε or PKCe) kinase inhibitor to enter human clinical testing. Preclinical VMD-102 anti-tumor activities in mouse liver/HCC tumor models and preclinical toxicology and pharmacology studies support this study.
Read the detailed description
Phase 1:
The Phase 1 dose escalation will evaluate escalating dose levels of VMD-102 in approximately 25 evaluable participants. This phase will assess the safety, PKs and tolerability of VMD-102 during cycle 1 (of 21-day cycle). Dose escalation will be guided according to the Bayesian Optimal Interval (BOIN) design to determine the next dose level based on dose-limiting toxicity (DLT) occurrence with participants of advanced HCC, MUM, RCC, NSCLC, and CRC to determine the MTD and the RP2D. Retrospective biomarker studies for the preclinical identified biomarkers may be carried out from tumor tissue and blood samples collected from participants.
Phase 2:
The Phase 2 dose expansion will employ a Bayesian Optimal Phase II (BOP2) design to enroll participants to assess the anti-tumor activity and safety of VMD-102 in Cohort 1 (approximately 43) participants with HCC, and Cohort 2 (approximately 43) participants with MUM, RCC, NSCLC and CRC. A biomarker guided enrollment criterion may be added via amendment. For each of two cohorts, once RP2D is determined, the Phase 2 expansion may be opened in both cohorts parallelly.
- Conditions
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer, Colorectal Cancer (CRC)
- Being tested
- VMD-102
- Medical subject headings
- Carcinoma, Hepatocellular, Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VMD-102Drug
Also called Single agent
A small organic molecule oral drug in the tablet form
| Study group | Role | What they receive |
|---|---|---|
| Phase 1 and Phase 2 | Experimental | Phase 1: The dose escalation will evaluate escalating dose levels of VMD-102 in approximately 25 participants. This phase will assess the safety, pharmacokinetics and tolerability of VMD-102 during cycle 1 (of 21-day cycle) with participants of advanced HCC, MUM, RCC, NSCLC, and CRC to determine the maximum tolerated dose (MTD) and the RP2D. Retrospective biomarker studies for the preclinical identified biomarkers may be carried out from tumor tissue and blood samples collected from participants.
Phase 2: The Phase 2 dose expansion will employ a Bayesian Optimal Phase II (BOP2) design to enroll participants to assess the anti-tumor activity and safety of VMD-102 in Cohort 1 (approximately 43) participants with HCC, and Cohort 2 (approximately 43) participants with MUM, RCC, NSCLC and CRC. A biomarker guided enrollment criterion may be added via amendment. For each of two cohorts, once RP2D is determined, the Phase 2 expansion may be opened in both cohorts parallelly. Receives: Drug: VMD-102 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number and severity of treatment-emergent adverse events (TEAE) (Phase 1)
TEAE
Measured: First cycle (21 days per cycle)
To determine the recommended Phase 2 dose (RP2D) for VMD-102 (Phase 1)
RP2D
Measured: First cycle (21 days per cycle)
Progression-Free Survival (PFS) (Phase 2)
Defined as the time from enrollment to tumor progression or death from any cause.
Measured: Up to 18 months
Secondary outcomes (7)
Area under the plasma concentration versus time curve (AUC) of VMD-102
AUC
Measured: On Day 1 and Day 15 of Cycle 1 (each cycle is 21 days)
Peak plasma concentration (Cmax) of VMD-102
Cmax
Measured: On Day 1 and Day 15 of Cycle 1 (each cycle is 21 days)
Incidence of Dose Limiting Toxicities
# of DLTs
Measured: During the Cycle 1 (each cycle is 21 days)
Objective Response Rate (ORR)
The proportion of patients with objective tumor response, as evaluated by the investigator, including cases of complete response (CR) and partial response (PR).
Measured: Up to 18 months
Disease Control Rate (DCR)
The proportion of patients with controlled tumor disease, as evaluated by the investigator, including cases of complete response (CR), partial response (PR), and stable disease (SD) (lasting for more than 4 weeks)
Measured: Up to 18 months
Duration of Response (DoR)
The time from the first assessment of complete response (CR) or partial response (PR) to the first assessment of progressive disease (PD) or death from any cause.
Measured: Up to 18 months
Overall Survival (OS)
The time from enrollment to death from any cause.
Measured: Up to 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2026
- Study start16 Jul 2026
- Primary completionMay 2031 (estimated)
- Study completionDec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular Carcinoma (HCC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 111 participants (estimated)
Sponsor and investigators
- Lead sponsor
- VM Discovery, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Jay Wu, PhD, Study chair, VM Discovery, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07636785
- Sponsor's protocol ID
- VMD-01C
- Acronym
- SPKTAHC
- Status last verified
- Aug 2026
- First submitted
- 4 May 2026
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided